Literature DB >> 16040967

Degradation of Chlamydia pneumoniae by peripheral blood monocytic cells.

Katerina Wolf1, Elizabeth Fischer, Ted Hackstadt.   

Abstract

Chlamydia pneumoniae is a common human respiratory pathogen that has been associated with a variety of chronic diseases, including atherosclerosis. The role of this organism in the pathogenesis of atherosclerosis remains unknown. A key question is how C. pneumoniae is transferred from the site of primary infection to a developing atherosclerotic plaque. It has been suggested that circulating monocytes could be vehicles for dissemination of C. pneumoniae since the organism has been detected in peripheral blood monocytic cells (PBMCs). In this study we focused on survival of C. pneumoniae within PBMCs isolated from the blood of healthy human donors. We found that C. pneumoniae does not grow and multiply in cultured primary monocytes. In C. pneumoniae-infected monocyte-derived macrophages, growth of the organism was very limited, and the majority of the bacteria were eradicated. We also found that the destruction of C. pneumoniae within infected macrophages resulted in a gradual diminution of chlamydial antigens, although some of these antigens could be detected for days after the initial infection. The detected antigens present in infected monocytes and monocyte-derived macrophages represented neither chlamydial inclusions nor intact organisms. The use of {N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]}-6-aminocaproyl-d-erythro-sphingosine as a vital stain for chlamydiae proved to be a sensitive method for identifying rare C. pneumoniae inclusions and was useful in the detection of even aberrant developmental forms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040967      PMCID: PMC1201216          DOI: 10.1128/IAI.73.8.4560-4570.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors.

Authors:  J Boman; S Söderberg; J Forsberg; L S Birgander; A Allard; K Persson; E Jidell; U Kumlin; P Juto; A Waldenström; G Wadell
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

2.  Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.

Authors:  J Gieffers; H Füllgraf; J Jahn; M Klinger; K Dalhoff; H A Katus; W Solbach; M Maass
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

3.  Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse.

Authors:  T C Moazed; C C Kuo; J T Grayston; L A Campbell
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

4.  Rabbit model for Chlamydia pneumoniae infection.

Authors:  I W Fong; B Chiu; E Viira; M W Fong; D Jang; J Mahony
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  T C Moazed; L A Campbell; M E Rosenfeld; J T Grayston; C C Kuo
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

6.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.

Authors:  J B Muhlestein; J L Anderson; E H Hammond; L Zhao; S Trehan; E P Schwobe; J F Carlquist
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

7.  Murine models of Chlamydia pneumoniae infection and atherosclerosis.

Authors:  T C Moazed; C Kuo; J T Grayston; L A Campbell
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

8.  Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae.

Authors:  N M Rothstein; T C Quinn; G Madico; C A Gaydos; C J Lowenstein
Journal:  J Infect Dis       Date:  2000-12-13       Impact factor: 5.226

9.  Chlamydia pneumoniae infection in human monocytes.

Authors:  S Airenne; H M Surcel; H Alakärppä; K Laitinen; J Paavonen; P Saikku; A Laurila
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

Review 10.  Chlamydia pneumoniae and cardiovascular disease.

Authors:  L A Campbell; C C Kuo; J T Grayston
Journal:  Emerg Infect Dis       Date:  1998 Oct-Dec       Impact factor: 6.883

View more
  14 in total

1.  Regulation of chlamydial infection by host autophagy and vacuolar ATPase-bearing organelles.

Authors:  Muhammad Yasir; Niseema D Pachikara; Xiaofeng Bao; Zui Pan; Huizhou Fan
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

2.  Opsonophagocytosis of Chlamydia pneumoniae by Human Monocytes and Neutrophils.

Authors:  Mads Lausen; Mathilde Selmar Pedersen; Nareen Sherzad Kader Rahman; Liv Therese Holm-Nielsen; Faduma Yahya Mohamed Farah; Gunna Christiansen; Svend Birkelund
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

3.  Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque.

Authors:  Yuri V Bobryshev; Murray C Killingsworth; Dihn Tran; Reginald Lord
Journal:  Virchows Arch       Date:  2008-06-06       Impact factor: 4.064

4.  Perforin-2 restricts growth of Chlamydia trachomatis in macrophages.

Authors:  K A Fields; R McCormack; L R de Armas; E R Podack
Journal:  Infect Immun       Date:  2013-06-10       Impact factor: 3.441

5.  Glycosylphosphatidylinositol anchoring directs the assembly of Sup35NM protein into non-fibrillar, membrane-bound aggregates.

Authors:  Karen E Marshall; Danielle K Offerdahl; Jonathan O Speare; David W Dorward; Aaron Hasenkrug; Aaron B Carmody; Gerald S Baron
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

6.  Chlamydia pneumoniae impairs the innate immune response in infected epithelial cells by targeting TRAF3.

Authors:  Katerina Wolf; Kenneth A Fields
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

7.  Survival of Chlamydia muridarum within dendritic cells.

Authors:  Jose Rey-Ladino; Xiaozhou Jiang; Brent R Gabel; Caixia Shen; Robert C Brunham
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

8.  Is C. Pneumoniae research in peril?

Authors:  Katerina Wolf
Journal:  Front Microbiol       Date:  2011-03-21       Impact factor: 5.640

9.  The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism.

Authors:  Xianbao He; Robert Berland; Samrawit Mekasha; Thomas G Christensen; Joseph Alroy; Igor Kramnik; Robin R Ingalls
Journal:  PLoS Pathog       Date:  2013-08-29       Impact factor: 6.823

10.  Chlamydia pneumoniae hides inside apoptotic neutrophils to silently infect and propagate in macrophages.

Authors:  Jan Rupp; Lisa Pfleiderer; Christiane Jugert; Sonja Moeller; Matthias Klinger; Klaus Dalhoff; Werner Solbach; Steffen Stenger; Tamas Laskay; Ger van Zandbergen
Journal:  PLoS One       Date:  2009-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.